Episode 26: ViaCyte, a functional cure for Type 1 diabetes?

Written by

ViaCyte‘s President and CEO Dr. Paul K. Laikind, PhD describes the “stem cell derived islet replacement therapy” they are currently taking through clinical trials. In this episode of Everybody Talks Corinna Cornejo and Scott Johnson talk about the excitement surrounding what’s being characterized as a “functional cure” for Type 1 diabetes and asking some serious questions. What’s the tipping point for being willing to undergo stem cell implantation like the procedure ViaCyte is testing? Does this really sound like a cure or is it something else?

ViaCyte is a privately-held regenerative medicine company focused on developing a cell replacement therapy for the treatment of diabetes.  Currently, ViaCyte is conducting a Phase 1/2 clinical trial of the company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. Meanwhile, Vox Pop Films is documenting this process and producing the documentary film The Human Trial.

Everybody Talks Diabetes Podcast Corinna Cornejo